Antidepressant, Serotonin Syndrome & Neuropsychiatric Toxicities
Comprehensive emergency toxicology protocol for psychotropic medication crises. Features electrocardiographic predictors of tricyclic antidepressant (TCA) toxicity (QRS > 100 ms and terminal R wave in aVR), protocolized sodium bicarbonate therapy, the Hunter criteria for Serotonin Syndrome vs. Neuroleptic Malignant Syndrome (NMS), cyproheptadine dosing, and emergency hemodialysis indications for acute and chronic lithium poisoning.
Resuscitation Quick Actions • First 2 Minutes
TCA ECG Triggers
QRS > 100 ms or terminal R wave in aVR > 3 mm -> Stat Sodium Bicarbonate 1-2 mEq/kg IV push
Target Bicarb pH
Titrate sodium bicarbonate continuous infusion targeting serum arterial pH 7.50 to 7.55 and QRS < 100 ms
Physostigmine Contraindication
Never administer Physostigmine in suspected TCA toxicity; causes fatal asystole and complete heart block
Serotonin Syndrome Antidote
Cyproheptadine 12 mg PO initial load, then 2 mg PO every 2 hours until clinical improvement
Lithium Dialysis Threshold
Level > 4.0 mEq/L (acute) or > 2.5 mEq/L with severe neuro symptoms, renal failure, or altered mental status
Bottom-Line Clinical Pearl
In tricyclic antidepressant (TCA) overdose, a QRS duration > 100 ms predicts seizures, while QRS > 160 ms predicts life-threatening ventricular dysrhythmias; administer immediate IV Sodium Bicarbonate (1-2 mEq/kg boluses) targeting arterial pH 7.50-7.55 and QRS narrowing. Physostigmine is strictly contraindicated in TCA toxicity. Differentiate Serotonin Syndrome (clonus, hyperreflexia, rapid onset) from NMS (lead-pipe rigidity, hyporeflexia, insidious onset).
Tricyclic antidepressants (Amitriptyline, Nortriptyline, Imipramine, Doxepin) remain among the deadliest prescription overdoses. Toxicity arises from five distinct pharmacological actions: 1) Myocardial fast sodium channel (Nav1.5) blockade, 2) Peripheral alpha-1 adrenergic receptor blockade (profound hypotension), 3) Central and peripheral muscarinic acetylcholine blockade (anticholinergic toxidrome), 4) Delayed rectifier potassium channel (IKr) blockade (QT prolongation), and 5) Central GABA-A chloride channel antagonism (intractable seizures):
| ECG Finding | Biochemical Mechanism | Clinical Predictor & Prognostic Value |
|---|---|---|
| QRS Duration > 100 ms | Phase 0 cardiac sodium channel inhibition slows intraventricular depolarization, producing a right bundle branch block morphology. | 33% Risk of Generalized Seizures: Mandates immediate intravenous Sodium Bicarbonate therapy. |
| QRS Duration > 160 ms | Severe, diffuse conduction slowing throughout the His-Purkinje system and ventricular myocardium. | 50% Risk of Life-Threatening Ventricular Dysrhythmias (Ventricular Tachycardia, Torsades de Pointes, Ventricular Fibrillation). |
| Terminal R Wave in aVR > 3 mm | Selective rightward terminal conduction delay: unopposed late depolarization directed superiorly and rightward toward lead aVR. | Highly sensitive and specific indicator of severe TCA myocardial sodium channel toxicity. |
| Terminal R/S Ratio in aVR > 0.7 | Deep S wave in Lead I and Lead aVL with tall R wave in aVR ('Rightward axis of the terminal 40 milliseconds'). | Early hallmark sign of impending hemodynamic collapse, even before marked QRS widening develops. |
The Sodium Bicarbonate Resuscitation Protocol: 1) Bolus 8.4% Sodium Bicarbonate (1 to 2 mEq/kg IV push) over 1-2 minutes; repeat every 3-5 minutes until the QRS narrows to < 100 ms and blood pressure improves. 2) Initiate continuous IV maintenance infusion: mix 150 mEq Sodium Bicarbonate in 1 Liter D5W and infuse at 2 to 3 times maintenance rate (200-250 mL/hr). 3) Serial arterial blood gases targeting arterial pH 7.50 to 7.55 (hyperalkalinization uncouples TCA from cardiac sodium channels, while the sodium load outcompetes drug binding). 4) For refractory cardiac arrest: administer 20% Intralipid (Lipid Emulsion Therapy) 1.5 mL/kg IV bolus.
Serotonin Syndrome and Neuroleptic Malignant Syndrome (NMS) represent life-threatening hyperthermic drug-induced encephalopathies. Because their treatments are fundamentally distinct and mutually contraindicated, rapid clinical differentiation is vital:
| Feature | Serotonin Syndrome (SS) | Neuroleptic Malignant Syndrome (NMS) |
|---|---|---|
| Causative Pharmacotherapy | Excessive Serotonin Stimulation: SSRIs, SNRIs, MAOIs, TCAs, Tramadol, Meperidine, Fentanyl, Dextromethorphan, Linezolid (antibiotic with MAOI activity), St. John's Wort, MDMA (Ecstasy). | Dopamine D2 Receptor Antagonism: Antipsychotics (Haloperidol, Fluphenazine, Chlorpromazine, Olanzapine, Risperidone) OR abrupt cessation of dopamine agonists (Levodopa, Bromocriptine). |
| Onset & Progression | RAPID ONSET (Within 6 to 24 Hours): Develops precipitously after dose initiation, dose escalation, or co-ingestion of two serotonergic drugs. Rapid resolution (< 24-48h) once discontinued. | INSIDIOUS ONSET (Over Days to Weeks): Evolves gradually over 3 to 14 days of neuroleptic therapy. Prolonged resolution (9 to 14 days) after drug discontinuation. |
| Neuromuscular Tone & Reflexes (THE CRITICAL DISTINCTION) | NEUROMUSCULAR EXCITATION (HYPERREFLEXIA & CLONUS): - Spontaneous, inducible, or ocular CLONUS (hallmark sign!) - Marked Hyperreflexia (Lower extremities >> Upper extremities) - Tremor, myoclonus, shivering. | SEVERE MUSCLE RIGIDITY ('LEAD-PIPE'): - Generalized, severe, lead-pipe or cogwheel rigidity throughout all extremities - HYPOREFLEXIA or normal deep tendon reflexes (clonus is absent). |
| Hunter Criteria Confirmation | In the presence of a serotonergic agent, diagnosis is confirmed by ONE of: 1. Spontaneous clonus 2. Inducible clonus + agitation/diaphoresis 3. Ocular clonus + agitation/diaphoresis 4. Tremor + hyperreflexia 5. Hypertonia + Temp > 38°C + ocular/inducible clonus. | Diagnostic Criteria: 1. Exposure to dopamine antagonist 2. Severe lead-pipe muscle rigidity 3. Hyperthermia (> 38°C) 4. Autonomic instability (BP lability, tachycardia) 5. Massive serum Creatine Kinase (CK) elevation (> 10,000-50,000 IU/L). |
| Targeted Emergency Antidote | 1. IV Benzodiazepines (Lorazepam 2-4 mg IV) 2. Cyproheptadine (5-HT2A antagonist): 12 mg PO initial loading dose, then 2 mg PO every 2 hours until symptom control 3. Active cooling. | 1. Discontinue all neuroleptics immediately 2. Aggressive crystalloid hydration for rhabdomyolysis 3. IV Benzodiazepines 4. Bromocriptine (dopamine agonist, 2.5-5 mg PO TID) or Dantrolene (ryanodine antagonist, 1-2.5 mg/kg IV). |
Lithium has an exceptionally narrow therapeutic index (0.6 to 1.2 mEq/L). It is excreted 100% unchanged by the kidneys, handled identically to sodium in the proximal convoluted tubule. Any state of volume depletion or sodium restriction (dehydration, thiazide diuretics, NSAIDs, ACE inhibitors) accelerates proximal tubular lithium reabsorption, producing severe toxicity:
| Toxicity Subtype | Clinical Presentation & Timing | Emergency Management & Dialysis Triggers |
|---|---|---|
| Acute Lithium Overdose (Ingestion) | Large single ingestion in a lithium-naive or maintenance patient. Predominantly Gastrointestinal symptoms early: severe nausea, vomiting, abdominal cramping, and profuse diarrhea. Serum levels correlate poorly with early CNS toxicity because lithium takes 24 hours to cross the blood-brain barrier. | 1. Aggressive IV hydration with 0.9% Normal Saline (restores GFR and promotes natriuresis/lithium excretion). 2. Whole bowel irrigation with Polyethylene Glycol (GoLYTELY 1-2 L/hr) for massive sustained-release ingestions (activated charcoal does NOT bind lithium). 3. Hemodialysis Trigger: Level > 4.0 mEq/L regardless of symptoms. |
| Chronic Lithium Toxicity (Accumulation) | Gradual accumulation due to impaired renal excretion. Characterized by Severe Neurological Toxicity: - Coarse resting tremor, ataxia, dysarthria, hyperreflexia - Choreoathetosis, fasciculations, myoclonus - Seizures, non-convulsive status epilepticus, coma - Risk of irreversible cerebellar damage (SILENT syndrome: Syndrome of Irreversible Lithium-Effectuated Neurotoxicity). | CRITICAL DIALYSIS THRESHOLDS: Perform Emergent Hemodialysis if: - Lithium level > 2.5 mEq/L with severe neurological signs (seizures, coma, altered mental status) - Lithium level > 2.5 mEq/L in the presence of acute kidney injury or chronic renal failure - Patient unable to tolerate aggressive volume expansion (decompensated heart failure, pulmonary edema). |
TCA Overdose: The Fatal Physostigmine Trap
In patients presenting with anticholinergic symptoms (mydriasis, tachycardia, delirium, dry flushed skin) from suspected tricyclic antidepressant overdose, PHYSOSTIGMINE IS ABSOLUTELY CONTRAINDICATED. In TCA toxicity, cardiac conduction is already severely impaired by fast sodium channel blockade; administering physostigmine (an acetylcholinesterase inhibitor) triggers profound, irreversible vagal bradycardia, high-grade AV block, asystole, and fatal cardiac arrest. Furthermore, never administer Class IA (procainamide, quinidine) or Class IC (flecainide) antiarrhythmics, which worsen sodium channel blockade. The sole first-line antidote for wide-complex dysrhythmias and conduction delay in TCA toxicity is Intravenous Sodium Bicarbonate.
Test Your Antidepressant, Serotonin Syndrome & Neuropsychiatric Toxicities Clinical Acumen
Directly launch an active-recall practice block from our 8,400+ validated COMLEX Level 1, 2-CE & 3 board question bank with complete explanations.
Related Emergency Protocols & Differentials
Toxicology: Toxidromes & Antidotes
General toxicology principles and antidotes.
Open Protocol Related EM ProtocolCardiac Dysrhythmias & Syncope
Wide-complex tachycardia differentiation.
Open Protocol Related EM ProtocolAcute Agitation & Psychiatric Emergencies
Severe agitation and neuroleptic side effects.
Open Protocol